<DOC>
	<DOC>NCT02002767</DOC>
	<brief_summary>This study is to evaluate the single-dose pharmacokinetics (PK), safety, and tolerability of GS-5816 in participants with severe renal impairment using matched healthy participants as a control group.</brief_summary>
	<brief_title>Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>General good health with stable chronic kidney disease in Severe Renal Impairment Group Screening labs within defined thresholds Creatinine clearance must be &lt; 30 mL/min for Severe Renal Impairment group, and â‰¥ 90 mL/min for Normal Renal Function group Females who are pregnant or nursing, or males who have a pregnant partner Infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with subject treatment and/or adherence to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>